The first phase of the large -scale biopharmaceutical manufacturing plant of Fujifilm Biotechnologies of $ 3.2 million on a large -scale biopharmaceutical cultivation in North Carolina is expected to begin this year.
Fujifilm Biotechnologies, a Fujifilm Corp subsidiary, based in Tokyo, announced for the first time the $ 2 billion plants project by 2021 and last year said that it would add a $ 1.2 million expansion. The plant will be the largest installation of manufacture of biopharmaceutical contracts of Fujifilm cell cultivation in North America.
Jacobs is the contractor for engineering, contracting and management of the construction of Fujifilm in both the initial and expansion project. Northern Carolina Biological and Pharmaceutical Manufacture “is quickly arising as a point of reference for innovation and resilience, driven by advances in digital technologies, modular design strategies and robust and robust. [project] Delivery methods, “said Koti Vadlamudi, executive vice president and general director of Jacobs’ World Business Units, in a statement.
“Cross -market solutions are further promoting the rise, with customers looking for water experience, environmental consulting and advanced permission and manufacturing,” he added.
0.3%
Growth rate planned for manufacturers’ capital investments for the next 12 months.
National Association of Manufacturers Q2 2025 Outlook Survey
The plant is being built in a site of 1 million feet southwest of Raleigh in Holly Springs, NC, will use eight bulk bioreactors of 20,000 liters, according to Fujifilm. He also said that the installation is designed for flexibility, allowing the company to add more bioreactors in the future to adapt to new initiatives and needs of its customers. The first expansion will add 400,000 square feet of manufacturing space and eight other 20,000 liter bioreactors for 2028.
